RxDoctor Payments Data

Georgiana Miller, DO

Family Medicine · Fallbrook, CANPI 1285814939

Payments from drug & device makers

$847in general payments, 2019–2025

Across 48 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$176
  • AbbVie$142
  • Novo Nordisk$140
  • GSK$114
  • Lilly USA, LLC$73
  • Galderma Laboratories, L.p.$59
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$847 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$98,919
Medicare patients
314
Services billed
1,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$78,284
EliquisApixaban57$45,849
MounjaroTirzepatide31$32,689
JardianceEmpagliflozin20$23,794
JanuviaSitagliptin Phosphate12$16,562
FarxigaDapagliflozin Propanediol17$9,660
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,242
LinzessLinaclotide12$8,127
Atrovent HfaIpratropium Bromide14$6,279
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,049
Levothyroxine Sodium322$4,160
SynthroidLevothyroxine Sodium33$2,592
Atorvastatin Calcium292$2,544
Telmisartan54$1,692
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$78,28473 claims
PfizerEliquis$42$45,84957 claims
Lilly USA, LLCMounjaro$73$32,68931 claims
Boehringer IngelheimJardiance$18$23,79420 claims
MerckJanuvia$16$16,56212 claims
AbbVieLinzess, Synthroid$142$10,71845 claims
AstraZenecaFarxiga$176$9,66017 claims
GSKTrelegy Ellipta$114$9,24215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Fallbrook

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →